Vera Therapeutics Prepares for Significant Investor Engagements
Vera Therapeutics Brings Innovations to the Forefront
Vera Therapeutics, Inc. (Nasdaq: VERA), a pioneering biotechnology firm located in Brisbane, California, specializes in developing and commercializing treatments for serious immunological diseases. The company's management team is gearing up to present at key investor conferences and engage in one-on-one meetings with potential investors.
Details of Upcoming Conferences
Guggenheim Securities Healthcare Innovation Conference
This conference will feature a fireside chat alongside one-on-one meetings. It is a fantastic opportunity for stakeholders and investors to gain insight into Vera’s projects and pipeline. The presentation is scheduled for November 13, 2024, at 9:30 AM EST in Boston. Participants can access the presentation through the webcast.
7th Annual Evercore ISI HealthCONx Conference
On December 5, 2024, Vera will present at the Evercore ISI HealthCONx Conference with a similar format of a fireside chat and one-on-one meetings. This platform allows for a deeper exploration into Vera’s innovative approaches to immunological diseases. Attendees can expect to hear firsthand about the latest advancements and product developments from the team.
Access to Webcasts
For those who cannot attend in person, Vera Therapeutics provides access to a replay of the webcasts for 90 days following each event. Interested individuals can find these recordings on the company’s Investor Calendar section of their website.
Vera Therapeutics: A Commitment to Innovation
At the heart of Vera's mission is a commitment to transforming care for patients suffering from severe immunological diseases. Their lead product candidate, atacicept, serves a crucial role in this mission. Atacicept is a fusion protein that is administered subcutaneously once a week. It functions by blocking B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), both critical components that drive the production of autoantibodies linked to autoimmune disorders such as IgAN (Berger’s disease) and lupus nephritis.
In addition to atacicept, Vera is advancing another promising therapy known as MAU868. This monoclonal antibody is designed to neutralize BK virus infections, which can have serious implications, particularly in patients who have undergone kidney transplants. Vera holds full global development and commercialization rights for both atacicept and MAU868, allowing them to lead the charge in developing life-changing therapies for patients worldwide.
Company Contact Information
If you seek further information regarding Vera Therapeutics or their innovative therapies, don't hesitate to reach out:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
Email: jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
Email: MHawtin@lifescicomms.com
Frequently Asked Questions
What is Vera Therapeutics focused on developing?
Vera Therapeutics is dedicated to developing transformative treatments for patients with serious immunological diseases.
What is atacicept?
Atacicept is a fusion protein that blocks key factors stimulating B cells and plasma cells, potentially reducing autoantibodies in autoimmune diseases.
When is Vera participating in investor conferences?
Vera will be presenting at the Guggenheim Securities Healthcare Innovation Conference on November 13, 2024, and the Evercore ISI HealthCONx Conference on December 5, 2024.
Where can I find the webcasts from the conferences?
Webcasts will be available for replay for 90 days after the conferences on the Investor Calendar section of Vera's website.
Who can I contact for more information about Vera Therapeutics?
You can contact Joyce Allaire at LifeSci Advisors for investor inquiries or Madelin Hawtin at LifeSci Communications for media requests.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.